Newsroom

LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Varonis Systems, Inc. (VRNS) Shareholders To Inquire About Securities Fraud Class Action...

SAN FRANCISCO--(BUSINESS WIRE)--Daniel Wheeler today announced his candidacy for the United States House of Representatives in California's 11th District, pledging to restore San Francisco's position as America's beacon of innovation, progress and common-sense leadership. San Francisco is overdue for representation by someone unbeholden to special interests or responsible for the misuse of public funds. Wheeler is laser focused on San Franciscans’ priorities: Economic Growth and Affordability:...

PUTEAUX, France--(BUSINESS WIRE)--Regulatory News: Déclaration des transactions sur actions propres Période du 5 au 9 janvier 2026 Emetteur : EMEIS (LEI : 969500LHIH3NT7PK1V89) (Paris:EMEIS) Catégories de titres : actions ordinaires (ISIN : FR001400NLM4) Descriptif du programme mis en ligne sur le site Internet de l’Autorité des Marchés Financiers le 12 janvier 2026 Rapport hebdomadaire sur les rachats d'actions du 5 au 9 janvier 2026   Nom de l'émetteur Code identifiant de l'émetteur (code LEI...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced the acquisition of CombinAbleAI and the launch of insitro’s TherML™ (Therapeutic Machine Learning) platform. The acquisition, which is expected to close in late January 2026, will complete insitro's full stack, modality-agnostic capability spanning small molecules, oligonucleotides, antibodies, and other complex biologics with precision – enabling biology to guide both mod...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Event Date Annual results 2025-2026 (April 2025-March 2026) Tuesday, June 16, 2026 General Meeting Thursday, September 10, 2026 Half-Year results 2026-2027 (April-September 2026) Tuesday, December 8, 2026 About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are design...

SAN FRANCISCO--(BUSINESS WIRE)--Owkin, the AI company on a mission to solve the complexity of biology, today announced the launch of its agentic infrastructure for biology, making its best-in-class AI agents available to the healthcare ecosystem. The announcement comes at the JPM Healthcare Conference 2026 and follows Owkin’s recent strategic partnerships and its just-announced integration with Claude for Healthcare and Life Sciences by Anthropic. Owkin, a 10-year-old AI company with $300 milli...

BOSTON--(BUSINESS WIRE)--The Board of Trustees of Liberty All-Star Equity Fund (NYSE: USA) has declared a distribution of $0.18 per share payable on March 9, 2026 to shareholders of record on January 22, 2026. This distribution is in accordance with the Fund’s current distribution policy of paying distributions on its shares totaling approximately 10 percent of its net asset value per year, payable in four quarterly installments of 2.5 percent. A portion of the distribution may be treated as pa...

DEERFIELD, Ill. and LEEDS, England--(BUSINESS WIRE)--Curion, a portfolio company of Summit Park, is pleased to announce the acquisition of Blue Yonder Research, a United Kingdom-based market research agency specializing in research and development (R&D) and innovation insights. The partnership strengthens Curion’s global delivery capabilities for multinational clients, expands its addressable market, and reinforces its position in core end markets where the company has built deep expertise...

SAN FRANCISCO--(BUSINESS WIRE)--Owkin, an AI company on a mission to solve the complexity of biology, today announced that its interoperable Pathology Explorer AI agent will be included in the launch of Claude for Healthcare and Life Sciences (HCLS) by Anthropic. This marks the first time a highly specialized, world-leading biological agent trained primarily on multimodal patient data is accessible through the Model Context Protocol (MCP) to a broad audience of healthcare and life sciences prof...

BOSTON--(BUSINESS WIRE)--Zelis®, a leading provider of healthcare technology solutions, announces the acquisition of Rivet, a leader in revenue cycle analytics. Building on the companies’ successful partnership, the acquisition underscores Zelis’ commitment to reduce administrative burden and improve financial operations for payers and providers. As part of Zelis, Rivet’s AI-enabled revenue cycle analytics will offer providers more visibility into claim payment and denials trends through action...